Twist Bioscience Co. (NASDAQ:TWST) Position Increased by Entropy Technologies LP

Entropy Technologies LP raised its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 62.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,483 shares of the company’s stock after buying an additional 5,555 shares during the quarter. Entropy Technologies LP’s holdings in Twist Bioscience were worth $497,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Artisan Partners Limited Partnership increased its holdings in shares of Twist Bioscience by 111.3% in the 4th quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock valued at $137,241,000 after purchasing an additional 1,961,621 shares during the period. ARK Investment Management LLC boosted its position in shares of Twist Bioscience by 6.3% in the fourth quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company’s stock valued at $265,881,000 after acquiring an additional 427,274 shares during the period. Norges Bank bought a new stake in shares of Twist Bioscience in the fourth quarter valued at approximately $10,766,000. Dimensional Fund Advisors LP boosted its position in shares of Twist Bioscience by 29.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company’s stock valued at $46,732,000 after acquiring an additional 284,884 shares during the period. Finally, Baillie Gifford & Co. boosted its position in shares of Twist Bioscience by 12.1% in the first quarter. Baillie Gifford & Co. now owns 1,227,528 shares of the company’s stock valued at $42,116,000 after acquiring an additional 132,770 shares during the period.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $53.56 on Friday. The stock has a fifty day moving average price of $48.37 and a two-hundred day moving average price of $39.82. Twist Bioscience Co. has a 52-week low of $14.42 and a 52-week high of $59.54. The firm has a market capitalization of $3.12 billion, a P/E ratio of -15.94 and a beta of 1.80.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.05. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The company had revenue of $75.30 million during the quarter, compared to analyst estimates of $70.70 million. During the same period last year, the company posted ($1.06) earnings per share. The firm’s quarterly revenue was up 25.1% compared to the same quarter last year. On average, equities research analysts predict that Twist Bioscience Co. will post -3.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on TWST. TD Cowen raised their target price on Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th. Guggenheim began coverage on Twist Bioscience in a research report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 target price for the company. The Goldman Sachs Group raised their target price on Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, July 9th. Robert W. Baird raised their target price on Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Finally, Evercore ISI raised their target price on Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Twist Bioscience presently has an average rating of “Buy” and a consensus target price of $49.75.

Insider Activity

In other news, COO Patrick John Finn sold 2,174 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $30.12, for a total value of $65,480.88. Following the completion of the sale, the chief operating officer now directly owns 176,206 shares in the company, valued at $5,307,324.72. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO Emily M. Leproust sold 4,163 shares of Twist Bioscience stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $37.13, for a total value of $154,572.19. Following the completion of the sale, the chief executive officer now directly owns 509,986 shares in the company, valued at $18,935,780.18. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Patrick John Finn sold 2,174 shares of Twist Bioscience stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $30.12, for a total value of $65,480.88. Following the completion of the sale, the chief operating officer now owns 176,206 shares of the company’s stock, valued at $5,307,324.72. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 19,570 shares of company stock worth $827,162. 3.92% of the stock is owned by corporate insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.